TML-ORP ML-22

TML-ORP ML-22 is a preclinical drug candidate being developed by Themis Medicare, an Indian pharmaceutical company specializing in anesthesia and critical care. Classified as a sedative-hypnotic, the drug is being developed as a "New Dosage Form," likely utilizing Themis's proprietary "ThemiMelt" technology to create an orally disintegrating tablet (ODT) or "melt" formulation. The candidate is part of Themis's pipeline of Novel Drug Delivery Systems (NDDS) aimed at improving the administration and onset of action for drugs used in sedation and anesthesia. While the specific active pharmaceutical ingredient (API) has not been publicly disclosed, the "ORP" code and the company's focus on anesthesia suggest it may be a reformulated version of an established sedative agent. The project is currently in the preclinical stage of development.

Other names

TML-ORP ML-22-Themis Medicare-New Dosage Form-Sedative Hypnotic